Updated:
Madrigal Pharmaceuticals
Madrigal Pharmaceuticals was founded in 2011 as a rebranding of Synta Pharmaceuticals, with Paul Friedman taking over as CEO and later becoming Chair of...
Madrigal Pharmaceuticals
Madrigal Pharmaceuticals was founded in 2011 as a rebranding of Synta Pharmaceuticals, with Paul Friedman taking over as CEO and later becoming Chair of the Board. The company originally pursued a pipeline focused on cardiovascular and metabolic diseases, but its trajectory shifted decisively toward nonalcoholic steatohepatitis (NASH), a chronic liver condition with no previously approved drug. Bill Sibold succeeded Friedman as CEO in 2023, bringing direct commercial-launch experience from his tenure at Sanofi to steer the company's transition from a development-stage biotech to an integrated pharmaceutical company. The firm's strategy centers on a single asset, resmetirom, a once-daily oral thyroid hormone receptor-beta agonist designed to resolve liver fibrosis and steatosis in NASH without the off-target toxicity profile that plagued earlier compounds. In March 2024, Madrigal secured accelerated FDA approval for resmetirom — marketed as Rezdiffra — targeting adults with NASH with moderate to advanced fibrosis, consistent with stages F2 and F3. The approval triggered a direct-to-specialist commercial deployment across the United States, positioning Madrigal against prospective competitors expected from Novo Nordisk and Eli Lilly, who are investigating incretin-based therapies in the same population. The company's pricing strategy set an annual wholesale acquisition cost of roughly $47,400, which sparked a positive reception from payers and health economists given the lack of alternatives (per Reuters, 2024). Following approval, Madrigal built out a specialized sales force targeting hepatologists and gastroenterologists, while also funding investigator-initiated studies to explore Rezdiffra's utility in compensated cirrhosis and in combination with GLP-1 agonists. The company reported $14.6 million in Rezdiffra net sales during the second quarter of 2024, the first partial quarter on the market, and raised its full-year 2024 revenue guidance in subsequent quarterly filings, signaling steady early adoption (per the firm's official communications, 2024). Madrigal operates from its headquarters in West Conshohocken, Pennsylvania, and has not disclosed alternative investment vehicles, external co-investment platforms, or a venture-capital arm, operating purely as a publicly traded commercial-stage biotech. What structurally separates Madrigal from the typical small-cap biotech is its sole-sufficiency and first-mover posture in a disease space that has frustrated dozens of well-capitalized programs for a decade. The company maintains full commercial rights to Rezdiffra in the United States, with no shared economics from a co-promotion partner, a feature that gives it an unusually concentrated risk/reward profile as it builds a category essentially from scratch.
General information
Firm type
Asset Manager
Year founded
2011
AUM
Undisclosed
Location
Region
North America
Country
United States
City
West Conshohocken
Corporate office
West Conshohocken, PA, United States
Principals
Bill Sibold
Chief Executive Officer
Paul Friedman
Chair of the Board
Sector focus
Frequently asked questions
What is Madrigal Pharmaceuticals' lead asset and what condition does it treat?
Madrigal's lead asset is Rezdiffra (resmetirom), an oral thyroid hormone receptor-beta agonist. It is the first FDA-approved therapy for nonalcoholic steatohepatitis (NASH) with moderate to advanced fibrosis, stages F2 and F3. The drug was approved in March 2024 under an accelerated pathway. It is designed to reduce liver fat accumulation, inflammation, and fibrosis without the systemic toxicity that affected earlier thyroid hormone-targeting candidates.
Who runs investment decisions at Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals is a publicly traded biotech company; capital-allocation decisions are made by its senior management team and Board of Directors, not a singular chief investment officer. CEO Bill Sibold and Chair Paul Friedman lead strategic deployment, which is currently concentrated entirely on the commercialization and lifecycle development of Rezdiffra. The company has not disclosed a dedicated internal investment committee or external capital-management arm.
Is Madrigal structured as a family office or does it manage third-party capital?
Madrigal is neither a family office nor an asset manager. It is a publicly listed commercial-stage pharmaceutical company trading on the Nasdaq under the ticker MDGL. The firm raises capital through equity offerings and convertible debt to fund operations, but it does not pool or manage third-party investor capital for returns in the manner of a fund manager.
Does Madrigal participate in fund commitments or only direct investments?
Madrigal does not make fund commitments or direct financial investments as a core activity. Its capital deployment is operational, directed into clinical trials, manufacturing scale-up, and the commercial build-out of its sales force for Rezdiffra. The company periodically licenses or acquires preclinical programs, but it is not structured as a corporate venture-capital group.
What is Madrigal's known posture on co-investments alongside external partners?
Madrigal does not have an external co-investment program. Its commercial strategy is defined by sole ownership of Rezdiffra's US rights; the company has actively avoided co-promotion or profit-sharing agreements that would dilute its economics. In the clinic, it funds investigator-initiated combination studies but retains full ownership of the core asset.
How does Madrigal's competitive position hold up against larger pharma entrants targeting NASH?
Madrigal is the only company with an approved therapy specifically for NASH fibrosis. Competitors such as Novo Nordisk and Eli Lilly are developing GLP-1-based compounds that may address obesity and steatosis but have faced challenges demonstrating fibrosis improvement on biopsy in Phase 3 trials. Madrigal's first-mover advantage and focused specialist targeting give it a window of exclusivity before any potential competitive approvals matieralize in the late 2020s.
Does Madrigal maintain philanthropic structures or a corporate foundation?
Madrigal has not publicly disclosed a separate philanthropic entity or dedicated corporate foundation. Its public disclosures focus on commercial operations and clinical research. Any patient-assistance programs for Rezdiffra are operated as part of its standard market-access and reimbursement infrastructure, not through a structurally separate foundation.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: